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BrdU labeled cells 18.72a7.25, 12.80*4.58 and 0.74kO.56 at I, 3 and 23 weeks respec- 
tively which correspond to the proliferation rate, was negligible after 23 weeks. 
Conclusions: The cellular growth over the filtering struts of the Diverter converges and 
reaches steady state within 6 months. Permanent arterial filtration by percutaneous 
Implantation of the fine wire based Diverler is feasible and free of risk of cellular over- 
growth and lumen obliteration. Our preliminary findings give hope for a new promising 
strategy for preventing embolic stroke. The approach would be particularly useful in eld- 
erly patients with chronic atrial fibrillation and contra-indications to anti-coagulation. 
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1181-120 Statins Promote Systemic Antioxidant Effects Through 
Specific Inflammatory Pathways 
Mehdi H. Shishehbor, Marie-Luise Brennan, Ronnier J. Aviles, Dennis L. Sprecher, 
Stanley L. Hazen. The Cleveland Clinic Foundation, Cleveland, OH 
Background: Formation of nitric oxide-derived oxidants and oxidative cross-linking of pro- 
teins both serve as potential mechanisms linking inflammation to development of athero- 
sclerosis. Nitrotyrosine (NOPTyr) and dityrosine (diTyr), specific molecular fingerprints of 
distinct oxidation pathways that convert LDL into an atherogenic form, are markedly 
enriched in human atheroma. Statins inhibit isoprenylation of key NAD (P) H oxidase 
components, leading to suppression in superoxide formation in vitro. The effects of 
statins on specific oxidation pathways in vwo are not known. 
Methods: Subjects (n=35) with hypercholesterolemia and no known coronary artery dis- 
ease were evaluated at baseline and following 12 weeks of therapy (atorvastatin, IO mgl 
d). Plasma levels of protein-bound NOPTyr and diTyr were determined by mass spec- 
trometry, and compared with alterations in levels of LDL-cholesterol (LDL-C) and high 
sensitive C-reactive protein (hsCRP). 
Results: Statin therapy caused significant reductions in the content (per mg plasma pro- 
tein) of mean NOPTyr and diTyr levels that were similar in magnitude to the reductions in 
mean LDL particle number (apoE-100) and total cholesterol (29% and 25%, respectively; 
P<O.OOl each). No significant correlations were noted between statin-induced changes 
in diTyr or NOPTyr and LDL-C or CRP. 
Conclwon: Statms promote potent systemic anti-Inflammatory and antioxldant effects 
independent of their influence on LDL and CRP. 
Characteristics Baseline 12 weeks Absolute 
(n=35) (n=35) and 
Percentage 
change 
P- 
Value 
Dityrosineltyrosine (micromolelmole) 34 * 11 23*7 -11 (32) <O.OOl 
Nitrotyrosineityrosine (micron-role/ 15*7 11*5 -4 (25) 0.017 
mole) 
High sensitive C-reactwe protem 
(“‘g/dL) 
0.26 zt 0.23 * -0.2 (II) 0.096 
0.32 0.33 
1181-121 Does Secondary Prevention With Statins Eliminate the 
Risk of Hyperhomocysteinemia? 
Kurt R. Jensen, Jeffrey L. Anderson, Joseph B. Muhlestem, Dale G. Renlund. Benjamin 
D. Home, Tami L. Bair, Qunyu LI. Donald L. LappB, LDS Hospital, Salt Lake City, UT, 
University of Utah, Salt Lake City UT 
Background: Hyperhomocysteinemia has emerged as a graded, independent risk factor 
for atherosclerosis. The molecular mechanism of vascular injury is uncertain. In a recent 
report, HMG CoA reductase mRNA and protein were found to be unregulated in human 
umbilical vein endothelial cells in response to increasing homocysteine (HCY) concentra- 
tions. Further, high HCY was associated with increased total cellular cholesterol content, 
and slmvastatin reduced cellular cholesterol and prevented HCY-induced suppression of 
nitric oxide production. 
Methods: We tested whether the mortality benefits of HMG CoA reductase inhibitors 
(statins) would be proportionately greater among coronary artery disease (CAD) patients 
with hyperhomocysteinemla. A total of 2,470 consecutive consenting patients who under- 
went angiography, had documented CAD, had a fasting HCY measurement, and were 
prospectively entered into the Intermountain Heari Collaborative Study Registry were 
studied. Multivariable Cox regressions were performed to assess the predictive value of 
HCY, statin use, and 15 other variables for survival. 
Results: Average age was 65*11 years; 77% were men; 27% were discharged on a sta- 
tin. During 3.8+1.6 years of follow-up, 379 (9.6%) died. HCY was higher among dying 
(median, 14.6 l,tmoVL) than survwing patients (13.0 pmol/L, p<O.OOl). The adjusted haz- 
ard ratio (HR) of death for HCY tertile 3 (>15.4 pmol/L) vs. 1 (<I 1.4 pmol/L) was 1.44 
(Cl=1 .I l-l .SS,p=O.OOS). As expected, statin therapy reduced the nsk of dying (HR=0.74, 
Cl=O.45-0.96, p=O.O2). However, proportionate reductions in mortality were no greater in 
the highest (HR=0.78) or middle (HR=0.74) than the lowest HCY tertile group (H&0.68) 
(~70.7 for statin’HCY interactions). 
Conclusion: High HCY is confirmed to be an independent risk factor for patients with 
established CAD. However, HCY levels do not define patient groups with differential sur- 
viva1 responses to statin therapy. Statins are indicated equally across the range of HCY 
plasma concentrations for secondary coronary prevention. Additional specific measures 
may be indicated for hyperhomocysteinemia. 
1181-122 Statins Reduce the Incidence of Atrial Fibrillation in 
Patients With Coronary Artery Disease 
Yinong Young-X& Charles M. Blatt. Susanna Bedell, Thomas Graboys, Brian Bilchik, 
Shmuel Ravid Lown Cardiovascular Research Foundation, Brookline. MA, Harvard 
School of Public Health, Boston, MA 
Background:Atrial Fibrillation (AF) is frequently associated factors that also predispose 
patlents to the development of coronary artery disease (CAD). We hypothesized that sta- 
tin therapy might have a beneficial effect on AF prevention in patients with CAD. Meth- 
od= The study cohort included patients with chronic stable CAD followed prospectively 
wth annual questionnaires. Clinically documented AF episodes were recorded through- 
out the study. The exposure of interest was statins use. We calculated percent-annual- 
ized incidence rate and ‘estimated the odds ratios (ORs) as well as 95% confidence 
intervals (Cl). Findings 482 study subjects had mean follow-up of four years and a rnax- 
imum of seven years. A total of 130 episodes of AF occurred in 80 patients. Comparing 
the 132 patients who had continuous use of statins and 192 patients who did not use any 
cholesterol-lowering drugs, statin use was associated with lower percent-annualized inci- 
dence rate of AF (2 vs. 3.9). Comparison of the incidence rate on statin to the incidence 
rate when patients were not using statin revealed that statin use was associated with 
lower risk of having AF (OR, 0.41; 95% Cl, 0.22-0.78). This association has remained 
significant after adjustment for potential confounders such as age, hypertension, diabe- 
tes, drug usage, and medical treatments. 
Interpretations Use of statins in patients with CAD appeared protective against AF by 
an unknown mechanism independent of cholesterol level and new cardiac events. 
i 
1181-123 Additive Effects of Ramipril and Atorvastatin on 
Inflammatory Cytokines Interferon-y, Tumor Necrosis 
Factor-a, Interleukin-6, and C-Reactive Protein in 
Diabetic Patients With Congestive Heart Failure 
Linda G. Tan, Stanley A. Tan, Lee S. Berk, Linda F. Lukman, Oakcrest Health Research 
Institute, Yucaipa. CA 
Background Interferon-y (lFN-& tumor necrosis factor-a (TNF-a) and C-reactive pro- 
tein (CRP) aggravate atherosclerosis and myocardial remodeling in CHF. Interleukin-6 
(IL-6) increases CAP. Diabetic patients have increased IFN-y, TNFa. IL-6 and CRP, and 
higher incidence of CHF. Statins have been reported to decrease CRP, and ACE inhibi- 
tors regress myocardial hypertrophy in CHF. 
Objective: We compared the effects of atorvastatin (A), ramipril (R), and combination of 
A+R on IFN-/, TNFa, IL-6 and CRP in diabetic patients with CHF. 
Methods 24 diabetics (hgb A,c 7.1+1.3%) with CHF (EF<30%) were divided into two 
groups. Group A received A 40 mgld, and group R IO mgld R. At 6 mo, R was added to 
group A, and A to group R. Lipid profile and the cytokines were measured and echocar- 
diograms were performed at baseline and every 2 mo. 
Results: Basal cyiokines levels were above normal in all subjects. In group A, the LDL 
cholesterol decreased significantly at 2 mo. HDL rise and LVH regression were observed 
at 4 mo. IFN?, TNF-a & IL-6 decreased at 4 mo, and CRP at 6 mo. In group R, LVH 
regressed and EF improved significantly at 4 mo. IFN?: TNF-a and IL-6 decreased at 2 
mo, and CRP at 4 mo. The magnitude of cytokines decreases were comparable in both 
group A & R. When R was added to group A, and A to group R, additive cytokine drops 
occurred. No significant changes in HDL, LDL, and total cholesterol were seen in group 
R. A lowered LDL cholesterol and increased HDL when added to group R, but no further 
improvement in CHF was noted. R significantly improved CHF and regressed LVH when 
added to group A. 
Conclusions Both A and R lower IFNy, TNF-a, IL-6 and CRP, and their effects are 
additive when combined. A lowers LDL and increases HDL, but only minlmalty improves 
CHF. R is a more potent LVH reducer and EF enhancer, but does not effect lipids. A+R 
are additive in lowering cytokines, potent lipid lowering agent, LVH reducer and EF 
enhancer. Thus combined atorvastatin and ramipril therapy can be beneficial for diabetic 
oatients with CHF. 
